Search Results
Your search for A matches 32982 pages
Showing 6001 - 6050Affirming Health Equity: A Model for Integrative Health Care
Guest Editor’s Note: Despite the increasing use of complementary modalities that include mind-body therapies and natural products, significant disparities exist in integrative health care. Contributing factors include access to care and affordability. In this installment of The ASCO Post’s...
Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC
As reported in The New England Journal of Medicine by Pasi A. Jänne, MD, PhD, and colleagues, findings in a phase II cohort of the multicohort KRYSTAL-1 phase I/II study indicate that the KRAS G12C inhibitor adagrasib showed activity in previously treated patients with unresectable or metastatic...
For Medicaid-Insured Patients With Cancer, Health Insurance Does Not Always Mean Health-Care Access
Although there has been a significant increase in the number of U.S. residents insured through Medicaid since the Patient Protection and Affordable Care Act was signed into law in March 2010, the ability of Medicaid-insured patients to access cancer care services has not been well understood. In a...
Study Examines Quality-of-Life Outcomes Among Patients Participating in Phase III Randomized Trials of Cancer Drugs
In an analysis that evaluated the outcomes of anticancer drug studies in the advanced disease setting with regard to patient quality of life (QOL), improved QOL outcomes were associated with improved overall survival but not with improved progression-free survival. Almost half of the studies that...
Zanubrutinib vs Bendamustine/Rituximab in Previously Untreated Patients With CLL or SLL
As reported in The Lancet Oncology by Constantine S. Tam, MBBS, PhD, and colleagues, an interim analysis in the phase III SEQUOIA trial has shown significantly improved progression-free survival with first-line zanubrutinib vs bendamustine/rituximab in patients with chronic lymphocytic leukemia...
Second-Line Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma Not Intended for HSCT
As reported in The Lancet Oncology by Sehgal et al, the phase II PILOT trial showed that the autologous, CD19-directed chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel produced a high response rate in the second-line treatment of patients with relapsed or refractory large...
Research Examines Which Demographic Is Most Likely to Use Medical Aid in Dying
Researchers analyzed data from each of the 5,329 patients across the United States who used medical aid in dying in the 23 years after Oregon became the first state to legalize the practice (in 1997) and found one demographic dominates the group: well-educated, White patients with cancer. These...
Deciphering the Elusive Origin and Pathways of Brain Metastases
The effective treatment of patients with brain metastases is an unmet need because, until fairly recently, patients with brain metastases were excluded from clinical trials of systemic therapies. However, the emergence of molecular targeted therapies has allowed a new treatment approach in patients ...
Addition of Brentuximab Vedotin to Chemotherapy in Patients With Stage III or IV Hodgkin Lymphoma: Overall Survival Analysis From ECHELON-1
As reported in The New England Journal of Medicine by Stephen M. Ansell, MD, PhD, and colleagues, an analysis at 6 years of follow-up in the phase III ECHELON-1 trial has shown significantly improved overall survival with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) vs ...
Clinical Practice Guidelines for Treatment and Prophylaxis of VTE in Patients With Cancer, Including Those Infected With COVID-19
In an article published in The Lancet Oncology, Farge et al outlined the International Initiative on Thrombosis and Cancer (ITAC) 2022 clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer, including those infected with COVID-19. The...
Tumor Grade and Response to Immune Checkpoint Inhibition in Recurrent or Metastatic Mucosal HNSCC
In a single-institution retrospective cohort study reported in JAMA Otolaryngology–Head & Neck Surgery, Alkhatib et al found a higher rate of response to immune checkpoint inhibitor treatment among patients with histologic high-grade vs low-grade recurrent or metastatic mucosal head and neck...
Study Explores Community Health Worker–Led Intervention’s Impact on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes
In a single-institution study reported in JAMA Oncology, Manali I. Patel, MD, MPH, MS, and colleagues found that the addition of a community health worker–led intervention to usual care resulted in reduced use of acute care, increased advance care planning documentation, increased use of palliative ...
New Antibody Therapy Shows Activity in Patients With Medulloblastoma
Effective and safe treatments are needed for medulloblastoma—the most common type of cancerous brain tumor in children—especially for patients whose cancer has spread to the spinal cord. A recent phase I clinical trial has generated promising results for a new blocking antibody therapy that targets ...
New Report Underscores Importance of Health Insurance Status and Cancer Stage at Diagnosis in Relation to Patient Survival
A new report published by Jingxuan Zhao, MPH, and colleagues in CA: A Cancer Journal for Clinicians showed that individuals without health insurance coverage were significantly more likely to be diagnosed with late-stage cancer and have worse survival rates after cancer diagnosis compared to...
Immune-Related Toxic Effects and Treatment Outcomes in Patients With Cancer and Autoimmune Diseases Receiving Immune Checkpoint Inhibitor Therapy
In a single-institution retrospective cohort study reported in JAMA Oncology, Han et al found that patients with autoimmune diseases had similar outcomes with immune checkpoint inhibitor (ICI) therapy for solid tumors as those without autoimmune diseases, with occurrence vs no occurrence of...
Addition of Atezolizumab to Neoadjuvant Pertuzumab/Trastuzumab and Docetaxel in HER2-Positive Early Breast Cancer
In the Korean phase II Neo-PATH trial reported in JAMA Oncology, Ahn et al found that neoadjuvant treatment with atezolizumab, pertuzumab/trastuzumab, and docetaxel produced a pathologic complete response in 61% of patients with HER2-positive stage II/III breast cancer treated with the regimen....
FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors
On July 14, 2022, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori) for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors. Two Trials The safety and...
Expert Point of View: Susan Slovin, MD, PhD
Invited discussant Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, pointed out there are no relevant serum biomarkers for disease progression and the challenges of interpreting response in metastatic castration-resistant prostate cancer. “We should have more definitive...
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted
On July 13, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Novavax COVID-19 vaccine, adjuvanted, for the prevention of COVID-19 caused by SARS–CoV-2 in individuals aged 18 years and older. “Authorizing an additional COVID-19 vaccine expands the...
Study Reveals Cancer Screening Decreased Worldwide During Height of COVID-19 Pandemic
A study that surveyed cancer screening data included in medical journals worldwide from January 2020 into December 2021 showed significant decreases in the number of screenings for breast, colorectal, and cervical cancers during the early phase of the COVID-19 pandemic. The findings of the study,...
President Biden Appoints Cancer Panel Members, and Cancer Cabinet Unveils Priority Actions
On July 13, President Joe Biden announced his intent to appoint Mitchel Berger, MD; Carol Brown, MD; and Elizabeth M. Jaffee, MD, to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President to advise him...
Do Bone Marrow Biopsies Aid in Response Assessment for Patients With Follicular Lymphoma?
In a pooled analysis of patients with follicular lymphoma treated in National Clinical Trials Network trials reported in the Journal of Clinical Oncology, Rutherford et al found evidence that bone marrow biopsies can be avoided in response assessment. The investigators stated, “Bone marrow biopsies ...
Immune Checkpoint Inhibitors for Solid Tumors in Kidney Transplant Recipients With Maintained Immunosuppression
In an Australian phase I study reported in The Lancet Oncology, Carroll et al found that maintaining baseline immunosuppression in kidney transplant recipients receiving immune checkpoint inhibitor treatment for advanced solid tumors did not appear to increase the risk of irretrievable allograft...
Expert Point of View: Madhav V. Dhodapkar, MBBS
“BCMA-targeting bispecific antibodies work, showing impressive single-agent activity in heavily pretreated multiple myeloma. This class of agents is likely to become an important component of future antimyeloma therapies, but we must learn how to optimally use them,” said Madhav V. Dhodapkar,...
Responses to Teclistamab Reported in Early-Phase Trial of Highly Refractory Multiple Myeloma
In patients with multiple myeloma exposed or refractory to three standard therapies, treatment with the bispecific antibody teclistamab produced strong and durable responses in the phase I/II MajesTEC-1 study.1 The results of weekly subcutaneous dosing of teclistamab in 165 patients were presented...
Michael Dickinson, MBBS, on DLBCL: Phase II Expansion Results on Glofitamab
Michael Dickinson, MBBS, of the Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and The University of Melbourne, discusses new data, which showed that fixed-duration glofitamab induces durable complete remissions with a favorable safety profile in patients with or refractory diffuse...
Geriatrics Experts Explore Relationship Between Heart Disease and Cancer
Experts’ discussions and recommendations addressing the interface between cancer and heart disease were published by Supriya Mohile, MD, MS, and colleagues in the Journal of the American Geriatrics Society, summarizing sessions from a virtual bench-to-bedside conference hosted by the American...
Poziotinib Shows Activity in EGFR Exon 20–Mutant NSCLC, With Efficacy Dependent on Insertion Location
A phase II clinical trial of poziotinib for patients with non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 mutations found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may ...
New Gene-Profiling Technology Reveals Potential Melanoma Biomarkers
Diagnosing melanoma clinically and under the microscope can be complicated by the presence of melanocytic nevi, otherwise known as birthmarks or moles that are noncancerous. The development of melanoma is a multistep process, where melanocytes mutate and proliferate. Properly identifying melanoma...
Antibody Response to SARS–CoV-2 Wild-Type Virus and Variants After mRNA Vaccination in Patients With NSCLC
In a single-institution study reported in the Journal of Clinical Oncology, Valanparambil et al found that one-quarter of patients with non–small cell lung cancer (NSCLC) had poor antibody responses to the SARS–CoV-2 wild-type (WT) strain after mRNA vaccination, and that neutralizing antibody...
Initial Risk Factors and ‘Time to Cure’ in Childhood and Young Adult Acute Lymphoblastic Leukemia
In an analysis of long-term follow-up of the UKALL2003 trial reported in the Journal of Clinical Oncology, Anthony V. Moorman, PhD, and colleagues found that whereas initial risk of relapse in children and young adults with acute lymphoblastic leukemia differed according to risk factors, risk...
Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma
As reported in The Lancet Oncology by Robin Kate Kelley, MD, and colleagues, the phase III COSMIC-312 trial has shown improved progression-free survival with cabozantinib plus atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma; interim analysis of overall survival showed...
CLN-081 Shows Selective Activity in NSCLC With EGFR Exon 20 Insertions
CLN-081, a novel agent targeted to non–small cell lung cancer (NSCLC) cells harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations—ie, the addition of nucleotide base pairs in exon 20 of the EGFR gene, a known oncogenic driver event—holds promise, according to the results of...
EAU22: Trial Shows New Imaging Technology May Be Less Accurate Than MRI in Detecting Prostate Cancer
A team of researchers in Australia and New Zealand reported that magnetic resonance imaging (MRI) scans may be able to detect prostate cancer more accurately than the newer, prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) scanning technique. The...
EAU22: ctDNA May Help to Predict Response to Atezolizumab in Patients With Bladder Cancer
Researchers who treated a group of patients with bladder cancer with the immunotherapy atezolizumab after they had undergone surgery have found that patients whose blood contained circulating tumor DNA (ctDNA) responded very well to the treatment. The study was presented at the European Association ...
Risk of Oropharyngeal Cancer After a Positive HPV16-E6 Serology Test
In an analysis from the Human Papillomavirus Cancer Cohort Consortium (HPVC3) reported in the Journal of Clinical Oncology, Robbins et al found substantial risks of oropharyngeal cancer over time among persons, particularly males, with positive results on human papillomavirus (HPV) 16-E6 serologic...
Rates of Major Adverse Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitors
In a single-institution Belgian study reported in the Journal of Clinical Oncology, Laenens et al found that major adverse cardiovascular events were “more common than currently appreciated” among patients receiving immune checkpoint inhibitors for cancer treatment. Study Details The study included ...
Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
In a phase II study reported in The Lancet Oncology, L. Elizabeth Budde, MD, PhD, and colleagues found that mosunetuzumab—a CD20 × CD3 T-cell–engaging bispecific antibody that redirects T cells to eliminate malignant B cells—produced a high rate of complete response in patients with relapsed or...
Former NCI Director Takes Stock of His Accomplishments and Looks Ahead to the Next Challenge
After nearly 5 years as Director of the National Cancer Institute (NCI), interrupted by 7 months as Acting Commissioner for the U.S. Food and Drug Administration (FDA), Norman E. “Ned” Sharpless, MD, left his position on April 29 to concentrate on his family and contemplate his next career choice....
History of Radiation Oncology in the United States
Part 1 of this two-part report described the beginnings of radiation oncology in the United States, including many of the field’s early pioneers and the rise of associated professional societies. In part 2, we will consider the advances in technology and biology that are the foundation of modern...
ASCO’s CancerLinQ and HealthVerity Collaborate to Accelerate Cancer Research
On June 8, 2022, CancerLinQLLC, a wholly owned nonprofit subsidiary of ASCO, and HealthVerity, Inc., announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies. The collaboration...
ASCO Guideline Update for Systemic Melanoma Therapy Addresses New Treatment Option for Uveal Melanoma
A rapid update to the ASCO guideline on systemic therapy for melanoma adds a new recommendation for the treatment of patients with metastatic uveal melanoma.1 The update follows the January 2022 U.S. Food and Drug Administration (FDA) approval of tebentafusp-tebn for patients with previously...
ASCO Guideline Update Aims to Improve Patient Outcomes for HER2-Positive Breast Cancer With Brain Metastases
Rapid developments over the past decade in the treatment of patients with advanced HER2-positive breast cancer may lead to better outcomes and improved quality of life for patients with brain metastases, according to findings incorporated into a new ASCO guideline update.1 “The difference this...
Mount Sinai Researcher Receives Award From the American Association of Indian Scientists in Cancer Research
Nina Bhardwaj, MD, PhD, Director of Immunotherapy at The Tisch Cancer Institute at Mount Sinai, has received the 2022 Lifetime Achievement in Cancer Research award from the American Association of Indian Scientists in Cancer Research (AAISCR). Dr. Bhardwaj is also Medical Director of the Vaccine...
CAR T-Cell Therapy Gave Me Back a High-Quality Life
A radiologist by training, I knew the minute I saw the results from my chest x-ray that I had multiple myeloma. In 2015, I was semiretired and had just taken up the game of golf. After making a big swing at the ball, I instantly felt pain in my ribs and thought I had either pulled an intercostal...
Moffitt Mourns the Loss of Research Giant Robert J. Gillies, PhD
Moffitt Cancer Center and the global research community have lost a great leader, scientist, and collaborator. Robert J. Gillies, PhD, died on June 7 after an extended illness. He was 69 years old. His recruitment in 2008 elevated Moffitt’s scientific stature, and his vision and work over the past...
Expert Point of View: Marianne E. Pavel, MD
Based on the final results of ECOG-ACRIN E2211, invited discussant Marianne E. Pavel, MD, of Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, concluded: “Capecitabine/temozolomide is a preferred regimen…, but temozolomide can still be an option in patients who do not tolerate...
Cautious Optimism About Mining for Patient-Centric Data
“If we have data, let’s look at it. If all we have are opinions, let’s go with mine.” —James Barksdale In this issue of The ASCO Post, Daniel Vorobiof, MD, and Irad Deutsch, principles at Belong.Life, a patient-oriented website whose self-described mission is to improve patient quality of life and ...
Shaping the Future of Cancer Care: The Value of Managing Aggregated Data From Patients’ Online Communities
In 2021, more than 1.9 million people in the United States were estimated to be diagnosed with cancer, and that number continues to increase yearly. Medical research is critical in prolonging survival and improving the quantity and quality of life of patients. Cancer research is one of the most...
